Then, miR-148a targeted the SMAD2-3′UTR, leading to a decreased expression of SMAD2, which inhibited TGFβ/SMAD2 signaling and attenuated the cancer stem cell (CSC)-like properties, suggesting a new approach for the treatment of human cancers [36]. The gene discussed is SMAD2; the disease is cancer.